Pharmacoepidemiology of the administration of antihypertensive drugs by doctors in the Voronezh region in comparison with the results of the PYTHAGOR IV study

Abstract

Background: To examine the pharmacoepidemiology of treatment for arterial hypertension (AH) in Russia, the PYTHAGOR study has been conducted since 2001, including PYTHAGOR I–II (2001–2002), PYTHAGOR III (2008), and PYTHAGOR IV (2013). Increasing the role of doctors of outpatient care in the pharmacotherapy of patients with AH creates prerequisites for conducting new pharmacoepidemiological studies.

Aim: To investigate the structure of prescriptions of antihypertensive drugs (AHD) by outpatient doctors at the regional level in comparison with the results of PYTHAGOR IV pharmacoepidemiological study.

Materials and methods: In 2018, a survey was conducted in the Voronezh region among 104 doctors, including 58 general practitioners (55.8%), 37 therapists (35.6%), and four cardiologists (3.8%). The average age of the doctors was 45.7 ± 13.5 years, the accumulated period of work was 21.0 ± 13.7 years, and the period of work in an outpatient clinic was 16.6 ± 12.4 years.

Results:  In the structure of doctors’ pREFERENCES in selecting free combinations of AHD, doctors preferred angiotensin-converting enzyme inhibitors (iACE; 90.3%), but they were prescribed more rarely than that in PYTHAGOR IV study (93.8%). The remaining AHD groups were used by doctors of the VR more often than in the PYTHAGOR IV study: beta-adrenoblockers, 89.4% (PYTHAGOR IV, 73.1%); diuretics, 88.4% (73.2%); calcium antagonists (CА), 86.5% (67.3%); angiotensin II receptor blockers (ARB), 81.7% (62.1%); imidazoline receptor agonists, 57.6% (13.3%). In the selection of fixed combinations of AHD: iACE or ARB with a diuretic was used in 71.9% and 36.4%, respectively, and iACE with CA in 46.2%. In the PYTHAGOR IV study, these combinations were used more rarely, i.e., in 33.3%, 28.0%, and 24.1%, respectively.

Conclusion: The data obtained indicate adherence of doctors to modern clinical guidelines for the pharmacotherapy of AH.

Keywords

arterial hypertension / antihypertensive drugs / fixed combinations / pharmacoepidemiology

References

[1] Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3):149–217. (In Russ). doi: 10.15829/1560-4071-2020-3-3786

[2] Кобалава Ж.Д., Конради А.О., Негода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 3. С. 149–217. doi: 10. 15829/1560-4071-2020-3-3786

[3] Leonova MV, Steinberg LL, Belousov YuB, et al. Results of pharmacoepidemiologic study of arterial hypertension PIFAGOR IV: physicians compliance. Russian Journal of Cardiology. 2015;(1):59–66. (In Russ). doi: 10.15829/1560-4071-2015-1-59-66

[4] Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., и др. РЕЗУЛЬТАТЫ фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV: приверженность врачей // Российский кардиологический журнал. 2015. № 1 (117). С. 59–66. doi: 10. 15829/1560-4071-2015-1-59-66

[5] Martsevich SY, Lukina YV, Zagrebelnyy AV, et al. on Behalf of the Working Groups of the Registries PROFILE and REСVASA. Combined Antihypertensive Therapy in Real Clinical Practice. Focus on Fixed Combinations of Antihypertensive Drugs (According to the Data of Outpatient Registries RECVASA and PROFILE). Rational Pharmacotherapy in Cardiology. 2017;13(3):323–9. (In Russ). doi: 10.20996/1819-6446-2017-13-3-323-329

[6] Марцевич С.Ю., Лукина Ю.В., Загребельный А.В., и др. Комбинированная антигипертензивная терапия в реальной клинической практике. Фокус на фиксированные комбинации анти-гипертензивных препаратов (по данным амбулаторных регистров РЕКВАЗА и ПРОФИЛЬ) // Рациональная фармакотерапия в кардиологии. 2017. Т. 13, № 3. С. 323–329. doi:10. 20996/1819-6446-2017-13-3-323-329

[7] Levashova OV. Analiz struktury naznacheniya gipotenzivnykh preparatov v usloviyakh g. Kurska v sravnenii s rezul’tatami farmakoepidemiologicheskogo issledovaniya PIFAGOR IV. In: Lazarenko VA, Mal GS, Boldina NV, editors. Farmakologiya serdtsa: materialy Vserossiyskoy nauchno-prakticheskoy konferentsii s mezhdunarodnym uchastiyem, posvyashchennoy 80-letiyu kafedry farmakologii (Kursk, 29 sentyabrya 2021). Kursk: MedTestInfo; 2017. P. 7–8. (In Russ).

[8] Левашова О.В. Анализ структуры назначения гипотензивных препаратов в условиях г. Курска в сравнении с результатами фармакоэпидемиологического исследования ПИФАГОР IV. В кн.: Лазаренко В.А., Мал Г.С., Болдина Н.В., ред. Фармакология сердца: материалы Всероссийской научно-практической конференции с международным участием, посвященной 80-летию кафедры фармакологии (Курск, 29 сентября 2021). Курск: МедТестИнфо; 2017. С. 7–8.

[9] Efanov AYu, Efanova SA, Pochinok EM, et al. Pharmacoepidemiological aspects of arterial hypertension treatment in Tyumen region. Medical Alphabet. 2018;1(3):51–5. (In Russ).

[10] Ефанов А.Ю., Ефанова С.А., Починок Е.М., и др. Фармакоэпидемиологические аспекты лечения артериальной гипертонии в Тюменской области // Медицинский алфавит. 2018. Т. 1, № 3. С. 51–55.

[11] Perepech NB, Shurygina VD, Tregubov AV. Doctors’ Adherence to the Guidelines on the Diagnostics and Treatment of Arterial Hypertension. Rational Pharmacotherapy in Cardiology. 2019;15(4):502–9. (In Russ.) doi: 10.20996/1819-6446-2019-15-4-502-509

[12] Перепеч Н.Б., Шурыгина В.Д., Трегубов А.В. Приверженность врачей рекомендациям по диагностике и лечению артериальной гипертонии // Рациональная фармакотерапия в кардиологии. 2019. Т. 15, № 4. С. 502–509. doi: 10.20996/1819-6446-2019-15-4-502-509

RIGHTS & PERMISSIONS

Kartashova E.S., Batischeva G.A., Zhdanova O.A., Sharapova Y.A.